Loading...

Parambir Dulai

TitleClinical Instructor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0956
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dulai PS, Peyrin-Biroulet L. Integrating Patient-reported Outcomes Into Treat to Target Monitoring Algorithms. Clin Gastroenterol Hepatol. 2018 Aug 25. PMID: 30153519.
      View in: PubMed
    2. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2018 Aug 24. PMID: 30165490.
      View in: PubMed
    3. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Aug 16. PMID: 30122356.
      View in: PubMed
    4. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Jun 27. PMID: 29946178.
      View in: PubMed
    5. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Jun 21. PMID: 29925913.
      View in: PubMed
    6. Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Jun 08. PMID: 29889233.
      View in: PubMed
    7. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease. Gastroenterology. 2018 May 29. PMID: 29857091.
      View in: PubMed
    8. Bessissow T, Dulai PS, Restellini S, Landry T, Bisschops R, Murad MH, Singh S. Comparison of Endoscopic Dysplasia Detection Techniques in Patients With Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Inflamm Bowel Dis. 2018 May 25. PMID: 29846600.
      View in: PubMed
    9. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Casteele NV, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 May 18. PMID: 29788240.
      View in: PubMed
    10. Fumery M, Patel NS, Boland BS, Dulai PS, Singh S, Sandborn WJ. Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 Apr 25. PMID: 29697797.
      View in: PubMed
    11. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 Mar 19; 24(4):871-876. PMID: 29509927.
      View in: PubMed
    12. Dulai PS, Buckey JC, Raffals LE, Swoger JM, Claus PL, O'Toole K, Ptak JA, Gleeson MW, Widjaja CE, Chang JT, Adler JM, Patel N, Skinner LA, Haren SP, Goldby-Reffner K, Thompson KD, Siegel CA. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol. 2018 Feb 16. PMID: 29453383.
      View in: PubMed
    13. Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis. 2018 Jan 24; 12(2):167-177. PMID: 29028958.
      View in: PubMed
    14. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. PMID: 29345635.
      View in: PubMed
    15. Dulai PS, Siegel CA. Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. Curr Drug Targets. 2018; 19(7):740-747. PMID: 28545382.
      View in: PubMed
    16. Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018 Feb; 9(2):65-72. PMID: 29387331.
      View in: PubMed
    17. Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2018 01; 154(1):37-45. PMID: 29122544.
      View in: PubMed
    18. Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 09 08; 9:CD011572. PMID: 28886205.
      View in: PubMed
    19. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 Mar; 16(3):343-356.e3. PMID: 28625817.
      View in: PubMed
    20. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017 May 02; 25(5):1054-1062.e5. PMID: 28467925.
      View in: PubMed
    21. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017 May; 65(5):1557-1565. PMID: 28130788.
      View in: PubMed
    22. Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, Gupta S, Murad MH. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ. 2016 Dec 05; 355:i6188. PMID: 27919915.
      View in: PubMed
    23. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, Singh S. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. PMID: 27916678.
      View in: PubMed
    24. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):110-121. PMID: 27899815.
      View in: PubMed
    25. Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. PMID: 27833391.
      View in: PubMed
    26. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):374-388.e4. PMID: 27780712.
      View in: PubMed
    27. Dulai PS, Sandborn WJ, Gupta S. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. PMID: 27679553.
      View in: PubMed
    28. Dulai PS, Sandborn WJ. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. PMID: 27461274.
      View in: PubMed
    29. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14; 315(22):2424-34. PMID: 27299618.
      View in: PubMed
    30. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug; 111(8):1147-55. PMID: 27296941.
      View in: PubMed
    31. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016 Nov; 65(5):1006-1016. PMID: 27312947.
      View in: PubMed
    32. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. PMID: 26835982.
      View in: PubMed
    33. Agoston AT, Strauss AC, Dulai PS, Hagen CE, Muzikansky A, Fudman DI, Abrams JA, Forcione DG, Jajoo K, Saltzman JR, Odze RD, Lauwers GY, Gordon SR, Lightdale CJ, Rothstein RI, Srivastava A. Predictors Of Treatment Failure After Radiofrequency Ablation For Intramucosal Adenocarcinoma in Barrett Esophagus: A Multi-institutional Retrospective Cohort Study. Am J Surg Pathol. 2016 Apr; 40(4):554-62. PMID: 26645729.
      View in: PubMed
    34. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. PMID: 26746169; PMCID: PMC4957452 [Available on 05/01/17].
    35. Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. PMID: 26618431.
      View in: PubMed
    36. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. PMID: 26005012.
      View in: PubMed
    37. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. PMID: 25884529.
      View in: PubMed
    38. Strauss AC, Agoston AT, Dulai PS, Srivastava A, Rothstein RI. Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study. Surg Endosc. 2014 Dec; 28(12):3366-72. PMID: 24950726.
      View in: PubMed
    39. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: Monotherapy with antitumour necrosis factor a agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. PMID: 24970900.
      View in: PubMed
    40. Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-a monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am. 2014 Sep; 43(3):441-56. PMID: 25110252.
      View in: PubMed
    41. Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):525-41. PMID: 25110257.
      View in: PubMed
    42. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1443-51; quiz e88-9. PMID: 24462626.
      View in: PubMed
    43. Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2013 Dec; 19(13):2927-36. PMID: 23867874; PMCID: PMC3938311.
    44. Dulai PS, Gordon SR, Rothstein RI. Response. Gastrointest Endosc. 2013 Jul; 78(1):191. PMID: 23820416.
      View in: PubMed
    45. Dulai PS, Pohl H, Levenick JM, Gordon SR, MacKenzie TA, Rothstein RI. Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study. Gastrointest Endosc. 2013 Apr; 77(4):534-41. PMID: 23290719.
      View in: PubMed
    46. Ghushe ND, Dulai PS, Trus TL. Laparoendoscopic transgastric resection of a submucosal mass at the gastroesophageal junction. J Gastrointest Surg. 2012 Dec; 16(12):2321. PMID: 23054899.
      View in: PubMed
    47. Dulai PS, Fisher ES, Rothstein RI. How may the transition to value-based payment influence gastroenterology: threat or opportunity? Clin Gastroenterol Hepatol. 2012 Jun; 10(6):609-11. PMID: 22624804.
      View in: PubMed
    48. Dulai PS, Rothstein RI. Disseminated sarcoidosis presenting as granulomatous gastritis: a clinical review of the gastrointestinal and hepatic manifestations of sarcoidosis. J Clin Gastroenterol. 2012 May-Jun; 46(5):367-74. PMID: 22334224.
      View in: PubMed
    49. von Renteln D, Dulai PS, Pohl H, Vassiliou MC, Rösch T, Rothstein RI. Endoscopic submucosal dissection with a flexible Maryland dissector: randomized comparison of mesna and saline solution for submucosal injection (with videos). Gastrointest Endosc. 2011 Oct; 74(4):906-11. PMID: 21802674.
      View in: PubMed